- Home
- NZF vs MIRM Comparison
NZF vs MIRM Comparison
Compare NZF & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NZF
- MIRM
- Stock Information
- Founded
- NZF 2001
- MIRM 2018
- Country
- NZF United States
- MIRM United States
- Employees
- NZF N/A
- MIRM N/A
- Industry
- NZF Finance Companies
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- NZF Finance
- MIRM Health Care
- Exchange
- NZF Nasdaq
- MIRM Nasdaq
- Market Cap
- NZF 2.2B
- MIRM 1.9B
- IPO Year
- NZF N/A
- MIRM 2019
- Fundamental
- Price
- NZF $12.01
- MIRM $45.18
- Analyst Decision
- NZF
- MIRM Strong Buy
- Analyst Count
- NZF 0
- MIRM 11
- Target Price
- NZF N/A
- MIRM $58.55
- AVG Volume (30 Days)
- NZF 496.8K
- MIRM 412.6K
- Earning Date
- NZF 01-01-0001
- MIRM 05-07-2025
- Dividend Yield
- NZF 4.67%
- MIRM N/A
- EPS Growth
- NZF N/A
- MIRM N/A
- EPS
- NZF N/A
- MIRM N/A
- Revenue
- NZF N/A
- MIRM $379,251,000.00
- Revenue This Year
- NZF N/A
- MIRM $29.51
- Revenue Next Year
- NZF N/A
- MIRM $20.27
- P/E Ratio
- NZF N/A
- MIRM N/A
- Revenue Growth
- NZF N/A
- MIRM 69.31
- 52 Week Low
- NZF $9.82
- MIRM $23.83
- 52 Week High
- NZF $12.29
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- NZF 57.15
- MIRM 63.46
- Support Level
- NZF $11.93
- MIRM $40.00
- Resistance Level
- NZF $12.06
- MIRM $47.43
- Average True Range (ATR)
- NZF 0.09
- MIRM 2.00
- MACD
- NZF 0.05
- MIRM 0.67
- Stochastic Oscillator
- NZF 96.09
- MIRM 88.68
About NZF Nuveen Municipal Credit Income Fund
Nuveen Municipal Credit Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and to enhance portfolio value relative to the municipal bond market by investing in an actively managed portfolio of tax-exempt municipal securities.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.